The following parameters are required from pathologic examination in order to calculate Residual Cancer Burden (RCB) after neoadjuvant treatment:

We obtained participant-level RCB results, and data on clinical and pathological stage, tumour subtype and grade, and treatment and follow-up in November, 2019, from patients (aged ≥18 years) with primary stage I-III breast cancer treated with neoadjuvant chemotherapy followed by …

2020年1月25日 · The residual cancer burden index categorizes patients with breast cancer into four groups (RCB 0–IV) based on level of residual disease after neoadjuvant therapy and several other factors as assessed by pathologists.

2019年12月13日 · Researchers from The University of Texas MD Anderson Cancer Center today reported results from a multi-center pooled analysis of breast cancer patients which found that residual cancer burden (RCB) after neoadjuvant treatment is an accurate long-term predictor of recurrence and survival in all breast cancer phenotypic subtypes.

残余肿瘤负荷 （RCB）是一个连续性数值，可以用来评估乳腺癌患者接受新辅助治疗后肿瘤残留的多少。 一些单中心分析研究已经证实，RCB可以很好的预测患者的预后，但是这些单中心的研究通常样本较小，因此很难得到准确的预测效能。

RCB index is a reliable prognostic score. RCB accurately identifies patients at a high risk of recurrence (RCB-III) with TNBC or HER2 -positive BC who must be offered second-line adjuvant therapies. Neoadjuvant chemotherapy (NAC), i. e. chemotherapy before surgery, is currently being used in poor prognosis breast carcinoma.

2024年12月9日 · The use of the residual cancer burden (RCB) for assessing breast cancer after neoadjuvant therapy (NAT) is increasingly common, but the prognostic difference between RCB 0 and RCB I is unclear.

2022年6月2日 · The small subset of pts with extensive residual disease (RCB-3) in both arms, 5.1% and 6.7%, respectively, had a poor prognosis. These results highlight the importance of neoadjuvant treatment with pembro for improving survival in pts with early TNBC, and identified a subset of pts for whom additional therapies will be needed.

残余肿瘤负荷(residual cancer burden，RCB)由MD Anderson 肿瘤中心提出，是一种 根据乳腺瘤床肿瘤和区域淋巴结评估新辅助治疗后的残余 肿瘤系统。 RCB 系统对于新辅助治疗后标本取材以及镜下 评估要求较为细致，在获得瘤床肿瘤最大二维横截面长径和 宽径(mm)、残余肿瘤细胞占瘤床百分比(%)和原位癌所占 比例(%)、淋巴结转移数量和淋巴结转移最大径(mm)等6 个参数后，可登录MD Anderson 网站在线计算或使用公式计 算RCB 评分，易于应用，具有可重复性。 …

RCB评估系统（residual cancer burden，RCB） 是美国MD Anderson癌症中心提出的残余肿瘤负荷评估系统，该系统由于评估了乳腺癌原发灶和淋巴结转移灶，目前临床医生和病理医生更加 …